The blood‑brain barrier (BBB) protects the brain from bacteria and other foreign substances. In doing so, it also prevents the uptake of 100 percent of large-molecule therapies and 98 percent of small molecule therapies.

The biopharmaceutical industry has conducted research into a variety of invasive and non-invasive techniques to deliver therapies through the BBB, including injection into the cranium, administration into a ventricle and BBB disruption, all of which have potentially serious safety implications for patients.

ArmaGen’s approach takes advantage of the body’s natural system to non-invasively deliver drugs across the BBB. The BBB selectively allows vital nutrients to pass from the bloodstream to the brain, through the presence of receptors that enable the entry of compounds such as insulin, transferrin (protein that transports iron) and low-density lipoproteins (LRP1, proteins that transport fat). ArmaGen’s technology platform targets the same receptors that transport these compounds to the brain.

Click here for an overview of ArmaGen’s research published in peer-reviewed publications.